Sing Tao Daily: The Nobel Prize Committee Responds to Xu’s Lawsuit

 By Liu Zhuo, from LA

The lawsuit filed by Rongxiang XU, the chairman of MEBO International Group, against the Nobel Prize Committee in Southern California last December has once drawn public attention. On 5^th March, XU confirmed that The Nobel Prize Committee has officially responded to the lawsuit of defamation and applied to the court to transfer the case from state system to federal system in LA. On 5^th March, many websites such as Reuters, Yahoo, and PR Newswire all posted this news and layout the news and comments of PR Newswire. During the exclusive interview with this reporter, XU said his lawsuit was filed on December 2012, which was related to the Nobel Prize in Physiology or Medicine. The Nobel Prize Committee officially responded to the lawsuit on 22^nd March and applied to the court to transfer the case to federal system. Xu’s lawyer said case transfer has no impact on the case itself but only serves as a procedural solution of defendant.

Dr. XU said lawsuit against the Nobel Prize Committee was not intended to ruin its reputation but only to clarify the misunderstanding about the “somatic cell induce into stem cell and regenerate tissue organ”. He discovered and proved via decades of research in human body regenerative science that this induction is human innate ability. This is a natural ability proved by his successful clinical application. According to XU, this induction can be done without the human engineered cell used by Nobel Prize winner 2012.

He also said in the indictment that he provided some cases after successful clinical application including patents and books describing and proving somatic cell induce into stem cell in situ and regeneration of physiological tissue organ. The cases included in situ skin regeneration after deep burn, amputated distal phalangette regeneration and restoration, regenerative restoration of scars as well as regeneration and rejuvenation of aged and atrophy gastrointestinal villi into young and dense villi.

Based on this proof, Dr. Xu believed human somatic cell can be induced into stem cell and regenerating tissue organ is a natural ability, which is not the result of adopting artificial engineered cell. However, the reason why Nobel Prize of Physiology or Medicine was given to those two winners was because they can induce somatic cell into what they called “pluripotent” cell via artificial nuclear transfer and cells reprogrammed. Dr. XU said the Nobel Prize Committee has the obligation to specifically describe the work which one by winners and has to admit that this has already proved by his clinical application. However, value of winners from The Nobel Prize Committee has misguided public understanding and also demeaned XU’s reputation and achievement which lead to the lawsuit.

He believed that human beings must be clear that the function of somatic cell induced into stem cell and regenerated tissue organ are the natural ability or the result of artificial engineered cell. This lawsuit is not only a defense of his scientific system but also a warrant to the public that life science should base on the reality.

He said Nobel Prize share high reputation around the world, thus the impact would be huge if they were wrong. The intention of this lawsuit was also well-meaning. He hope that the mass spare more attention on the trends and development of life science. The main purpose of this lawsuit was to help scientific institute to know scientific research should comply with life attributes but not anti-life attributes. This is a war between compliance with life attributes and transformation of lives.

Rongxiang Xu sued the Nobel Prize Committee and its 50 members who participate the selection of Nobel Prize of Medicine 2012 that offer these awards to John Gordon and Shinya Yamanaka and ignore Xu’s cutting-edge achievements in this field. In 2002, he applied the patent “Physiological tissue repair and functional organ regeneration by cultivation of regenerative stem cells in vivo and in situ”, with U.S. patent number: 6991813B2.